DIVI S LABORATORIES LTD vs EMCURE PHARMACEUTICALS L

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and EMCURE PHARMACEUTICALS L (EMCURE) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs EMCURE on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

74.93
P/E ratio
36.57
10.72
P/B ratio
7.11
0.44%
Dividend yield
0.17%
₹96.73
EPS
₹48.76

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
20.10%
22.00%
Return on capital
24.00%
33.00%
EBITDA margin
20.00%
24.32%
Net margin
10.22%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
15.42%
12.10%
Profit CAGR (3Y)
18.75%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.92L Cr
Market cap
₹33,810 Cr
₹10,560 Cr
Revenue
₹9,204 Cr
₹2,568 Cr
Net profit
₹941 Cr
0.00
Debt / equity
0.31
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 10.8 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
EMCURE PHARMACEUTICALS L
  • ["Stock is trading at 7.06 times its book value"]
DIVI S LABORATORIES LTD full analysis EMCURE PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

DIVI S LABORATORIES LTD vs EMCURE PHARMACEUTICALS L: Share Price, Valuation & Which to Buy | DocStoX